Day: September 17, 2020

Efecte Plc – Managers’ transactions – Hovi

Written by Customer Service on September 17, 2020. Posted in Public Companies.

Efecte Plc – Managers’ transactions – Hovi____________________________________________ Person subject to the notification requirementName: Hovi, NiinaPosition: Other senior managerIssuer: Efecte PlcLEI: 7437005U8P0KDN6RKW34 Notification type: INITIAL NOTIFICATIONReference number: 7437005U8P0KDN6RKW34_20200917111116_28____________________________________________ Transaction date: 2020-09-16Venue not applicableInstrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENTInstrument name: Efecte Oyj 2018C-optionNature of the transaction: ACCEPTANCE OF A STOCK OPTION(X) Linked to stock option programme Transaction details(1): Volume: 7000 Unit price: 0.00 EUR Aggregated transactions(1): Volume: 7000 Volume weighted average price: 0.00 EUR Further inquiries:Taru MäkinenCFOEfecte Plctaru.makinen@efecte.com+358...

Efecte Oyj – Johdon liiketoimet – Hovi

Written by Customer Service on September 17, 2020. Posted in Public Companies.

Efecte Oyj – Johdon liiketoimet – Hovi____________________________________________ IlmoitusvelvollinenNimi: Hovi, NiinaAsema: Muu ylin johtoLiikkeeseenlaskija: Efecte OyjLEI: 7437005U8P0KDN6RKW34 Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 7437005U8P0KDN6RKW34_20200917111116_28____________________________________________ Liiketoimen päivämäärä: 2020-09-16Kauppapaikka ei sovelluInstrumentti tyyppi: RAHOITUSINSTRUMENTTI, JOKA LIITTYY OSAKKEESEEN TAI VIERAAN PÄÄOMAN EHTOISEEN INSTRUMENTTIINInstrumentin nimi: Efecte Oyj 2018C-optioLiiketoimen luonne: OSAKEOPTION HYVÄKSYMINEN(X) Liiketoimi liittyy osakeoptio-ohjelman toteuttamiseen Liiketoimien yksityiskohtaiset tiedot(1): Volyymi: 7000 Yksikköhinta: 0.00 EUR Liiketoimien yhdistetyt tiedot(1): Volyymi: 7000 Keskihinta: 0.00 EUR Lisätietoja:Taru MäkinenTalousjohtajaEfecte...

Address change of AS Baltika

Written by Customer Service on September 17, 2020. Posted in Public Companies.

AS Baltika announces that as of 01 October 2020 the company’s new legal address and actual location is Valukoja 10, 11415 Tallinn, Estonia. AS Baltika telephone is +372 6302700. Other contact information of AS Baltika will remain the same. AS Baltika subsidiary Baltman OÜ new legal and actual location will also be from 01 October 2020 Valukoja 10, 11415 Tallinn, Estonia. Flavio PeriniMember of Management Board, CEOflavio.perini@baltikagroup.com

AS Baltika aadressi muudatus

Written by Customer Service on September 17, 2020. Posted in Public Companies.

AS Baltika annab teada, et alates 01.10.2020 on ettevõtte uus registrijärgne aadress ning tegelik asukoht Valukoja 10, 11415 Tallinn, Eesti Vabariik. AS Baltika kontakttelefon on +372 6302700. AS Baltika muud kontaktandmed jäävad samaks. AS Baltika tütarettevõtte Baltman OÜ uus registrijärgne aadress ning tegelik asukoht on alates 01.10.2020 samuti Valukoja 10, 11415 Tallinn, Eesti Vabariik.Flavio PeriniJuhatuse liige, tegevjuhtflavio.perini@baltikagroup.com

3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma

Written by Customer Service on September 17, 2020. Posted in Public Companies.

NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos evaluating commercialization options for NLC-001 WorldwideNEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on developing and distributing comprehensive solutions for COVID-19, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that NLC Pharma has added the dietary supplement NLC-001 to its joint venture with Todos Medical. NLC-001 is an orally administered proprietary blend of plant extracts that includes a...

Invesco Ltd.: Form 8.3 – G4S PLC

Written by Customer Service on September 17, 2020. Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION2. POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8...

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Written by Customer Service on September 17, 2020. Posted in Public Companies.

SEATTLE, Sept. 17, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced a positive interim safety assessment from the second cohort of healthy participants in the Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. This second group of eight participants received a single escalated dose of either AT-301A (placebo) or AT-301B (active drug). The blinded, positive assessment by the safety committee allows the study to now enroll the next cohort, which will be the third of a total of four cohorts and the first of two multi-dose, placebo controlled cohorts.“This second...

Huntington Ingalls Industries Awards 193 Scholarships for the 2020-2021 School Year Through Annual Scholarship Fund

Written by Customer Service on September 17, 2020. Posted in Public Companies.

NEWPORT NEWS, Va., Sept. 17, 2020 (GLOBE NEWSWIRE) — Huntington Ingalls Industries (NYSE: HII) announced today that the HII Scholarship Fund, now in its fifth year, has awarded 100 new scholarships for the 2020-2021 school year. Additionally, the fund renewed 93 previously active scholarships. To date, 767 scholarships have been awarded or renewed for a total of more than $2 million.The HII Scholarship Fund was formed to provide financial assistance to dependent children of HII employees who are pursuing a post-secondary college or technical/vocation degree and to dependent children who are enrolled in quality pre-kindergarten school readiness programs. For the fifth year in a row, HII President and CEO Mike Petters declined all but $1 of his annual salary to fund the program that has helped provide educational opportunities to...

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

Written by Customer Service on September 17, 2020. Posted in Public Companies.

Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020Panelists Include Representatives from IAVI, Merck and Tonix PharmaceuticalsNEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will host a live webinar on Thursday, September 24, 2020 at 10:00 a.m. ET to discuss the concept of two types of immune responses – antibody vs. T Cell – as well as provide an overview of the challenges of developing an effective vaccine.Participating panelists for the event will be:Swati Gupta, Vice President and Head of Emerging Infectious Diseases and Scientific Strategy, IAVI. Click HERE for full bio.Seth Lederman, M.D., Co-Founder and CEO, Tonix Pharmaceuticals. Click HERE for full...

Chicken Soup for the Soul Entertainment Announces Historical Drama ‘Robert the Bruce’ Comes to Crackle as AVOD Exclusive October 1

Written by Customer Service on September 17, 2020. Posted in Public Companies.

COS COB, Conn., Sept. 17, 2020 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment Inc. (Nasdaq: CSSE), one of the largest operators of streaming advertising-supported video-on-demand (AVOD) networks, today announced that historical action-drama Robert the Bruce will be exclusively available for free on Crackle beginning Thursday, October 1.The film stars Angus Macfadyen as the title character and explores events in Scotland following the action seen in Mel Gibson’s Oscar-winning film Braveheart where Macfadyen first played the Scottish king. Jared Harris (The Crown) co-stars as Robert the Bruce’s nemesis John Comyn, alongside Anna Hutchison (The Cabin In The Woods), Patrick Fugit (Gone Girl), Zach McGowan (Black Sails), Gabriel Bateman (American Gothic), Talitha Eliana-Bateman (Geostorm), Emma Kenney (Roseanne), Shane Coffey...

Day: September 17, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals